Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

PubWeight™: 14.06‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMID 19762550)

Published in Chest on September 17, 2009

Authors

Gregory Y H Lip1, Robby Nieuwlaat, Ron Pisters, Deirdre A Lane, Harry J G M Crijns

Author Affiliations

1: University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK. g.y.h.lip@bham.ac.uk

Articles citing this

(truncated to the top 100)

Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ (2011) 5.84

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA (2014) 3.59

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation (2014) 3.28

Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol (2014) 2.94

Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J (2014) 2.32

Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest (2014) 2.26

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J (2015) 2.25

Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 2.17

Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate. Circulation (2015) 2.12

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One (2013) 1.97

All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J (2013) 1.92

The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart (2013) 1.90

Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation (2013) 1.63

Clinical Prediction Models for Cardiovascular Disease: Tufts Predictive Analytics and Comparative Effectiveness Clinical Prediction Model Database. Circ Cardiovasc Qual Outcomes (2015) 1.62

Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ (2012) 1.61

Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol (2011) 1.58

Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation (2014) 1.53

Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord (2015) 1.52

Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract (2012) 1.46

Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation. Europace (2016) 1.43

National Trends in Ambulatory Oral Anticoagulant Use. Am J Med (2015) 1.41

Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation. Am J Cardiovasc Drugs (2012) 1.41

Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients. Europace (2013) 1.40

Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll Cardiol (2016) 1.39

Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart (2012) 1.38

Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ (2013) 1.33

Update on anti-coagulation in atrial fibrillation. QJM (2011) 1.28

Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation: The Prospective, Randomized, Controlled, Noninferiority FreezeAF Study. Circulation (2015) 1.21

Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. Br J Gen Pract (2015) 1.16

Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc (2013) 1.15

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J (2016) 1.14

A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc (2013) 1.14

Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med (2012) 1.13

Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One (2011) 1.10

Long-term prescribing of new oral anticoagulants. Aust Prescr (2016) 1.05

Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. Clin Res Cardiol (2015) 1.05

Managing atrial fibrillation in the global community: The European perspective. Glob Cardiol Sci Pract (2013) 1.04

The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study. Am Heart J (2011) 1.03

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J (2013) 1.03

Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart (2014) 1.02

Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes. Neth Heart J (2014) 1.00

The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation. Vasc Health Risk Manag (2011) 0.99

Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. Am J Kidney Dis (2015) 0.99

European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol (2015) 0.99

Clinical implications of recent trials on anticoagulation in patients with atrial fibrillation. Res Cardiovasc Med (2012) 0.98

Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest (2011) 0.98

Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions. Curr Cardiol Rev (2012) 0.98

CHADS2 and CHA2DS2-VASc Scores Predict the Risk of Ischemic Stroke Outcome in Patients with Interatrial Block without Atrial Fibrillation. J Atheroscler Thromb (2016) 0.98

Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. Eur Heart J (2013) 0.97

Atrial fibrillation: its prevalence and risk factor profile in the German general population. Dtsch Arztebl Int (2012) 0.97

The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J (2014) 0.97

CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol (2013) 0.96

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc (2016) 0.93

A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur Heart J (2012) 0.93

Anticoagulation in atrial fibrillation. BMJ (2014) 0.93

The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. Clin Res Cardiol (2015) 0.93

Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol (2014) 0.92

Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92

Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007. Eur J Clin Pharmacol (2012) 0.92

Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk. Clin Res Cardiol (2015) 0.91

Galectin 3 and incident atrial fibrillation in the community. Am Heart J (2014) 0.91

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag (2014) 0.91

Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ (2011) 0.90

The association between mean platelet volume and chronic atrial fibrillation and the presence of thrombotic events. Biomed Rep (2015) 0.90

Atrial fibrillation in the elderly. J Geriatr Cardiol (2012) 0.90

Controversies in cardioembolic stroke. Curr Treat Options Cardiovasc Med (2015) 0.90

Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review. Cardiol Res Pract (2013) 0.90

Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting. J Am Heart Assoc (2016) 0.89

Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty. BMC Nephrol (2013) 0.89

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev (2015) 0.89

Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. Ther Adv Drug Saf (2014) 0.89

A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol (2014) 0.89

Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. J Interv Card Electrophysiol (2013) 0.89

Choices in the use of ICD-9 codes to identify stroke risk factors can affect the apparent population-level risk factor prevalence and distribution of CHADS2 scores. Am J Cardiovasc Dis (2012) 0.88

Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care. Int J Cardiol (2015) 0.88

Left atrial appendage closure to prevent stroke in patients with atrial fibrillation. Circulation (2014) 0.88

Increased risk of ischemic stroke in patients with mild traumatic brain injury: a nationwide cohort study. Scand J Trauma Resusc Emerg Med (2014) 0.88

Hospital trends of admissions and procedures for acute leg ischaemia in England, 2000-2011. Ann R Coll Surg Engl (2015) 0.88

CHA2 DS2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. Eur J Heart Fail (2016) 0.88

Impact of prescribed medications on patient safety in older people. Ther Adv Drug Saf (2012) 0.88

Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis. Heart Vessels (2013) 0.88

Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open (2012) 0.87

Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. Biomed Res Int (2014) 0.87

Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation. J Geriatr Cardiol (2016) 0.87

Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol (2015) 0.87

Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. Clin Cardiol (2012) 0.87

Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87

Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry. Clin Res Cardiol (2015) 0.86

Mechanical antithrombotic intervention by LAA occlusion in atrial fibrillation. Nat Rev Cardiol (2013) 0.86

Clinical considerations of anticoagulation therapy for patients with atrial fibrillation. J Zhejiang Univ Sci B (2012) 0.86

Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open (2012) 0.86

Prediction of left atrial thrombi in patients with atrial tachyarrhythmias during warfarin administration: retrospective study in Hyogo College of Medicine. Heart Vessels (2015) 0.86

Stroke prevention in atrial fibrillation: concepts and controversies. Curr Cardiol Rev (2012) 0.86

Non-Traumatic Spontaneous Spinal Subdural Hematoma in a Patient with Non-Valvular Atrial Fibrillation During Treatment with Rivaroxaban. Am J Case Rep (2015) 0.86

Treatment of risk factors to prevent stroke. Neurotherapeutics (2011) 0.86

Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med (2013) 0.86

Articles by these authors

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37

Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol (2010) 4.78

Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69

Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46

Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry (2007) 4.44

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol (2012) 3.55

Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol (2012) 3.49

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05

Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol (2005) 2.93

Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86

Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81

Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59

Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials. BMJ (2013) 2.58

Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol (2010) 2.50

Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest (2005) 2.50

Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry (2006) 2.41

The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest (2012) 2.33

Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31

Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J (2005) 2.28

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22

Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol (2011) 2.19

Who is at risk of post-MI depressive symptoms? J Psychosom Res (2005) 2.18

Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol (2009) 2.16

Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol (2004) 2.10

Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA (2008) 2.09

Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol (2013) 2.08

Atrial fibrillation. Lancet (2011) 2.05

Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01

Relation of levels of serum lipoproteins to depression after acute myocardial infarction. Am J Cardiol (2002) 1.92

Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91

Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation (2012) 1.91

Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol (2009) 1.87

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84

Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke (2010) 1.79

Depression following myocardial infarction: first-ever versus ongoing and recurrent episodes. Gen Hosp Psychiatry (2005) 1.76

Acute results of transvenous cryoablation of supraventricular tachycardia (atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia). J Cardiovasc Electrophysiol (2002) 1.72

Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol (2005) 1.71

Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J (2005) 1.71

Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace (2008) 1.68

Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace (2012) 1.67

Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J (2008) 1.64

Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J (2003) 1.63

Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace (2011) 1.61

Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J (2011) 1.60

The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace (2010) 1.59

Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace (2010) 1.59

Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace (2011) 1.57

Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate. J Cardiovasc Electrophysiol (2004) 1.57

Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J (2008) 1.57

Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56

Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J (2004) 1.54

Calculation of effective VV interval facilitates optimization of AV delay and VV interval in cardiac resynchronization therapy. Heart Rhythm (2006) 1.54

Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. Heart Rhythm (2012) 1.53

Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm (2005) 1.52

The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest (2005) 1.51

Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J (2008) 1.51

Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension: the West Birmingham Malignant Hypertension study. J Hypertens (2012) 1.51

The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol (2011) 1.51

How to enhance acute outcome of electrical cardioversion by drug therapy: importance of immediate reinitiation of atrial fibrillation. J Cardiovasc Electrophysiol (2002) 1.45

Clinical and echocardiographic correlates of intra-atrial conduction delay. Europace (2011) 1.45

Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation (2009) 1.43

Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace (2013) 1.42

Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? Heart Rhythm (2005) 1.42

Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J (2007) 1.42

RR-interval irregularity precedes ventricular fibrillation in ST elevation acute myocardial infarction. Heart Rhythm (2009) 1.42

Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol (2007) 1.42

Atrial natriuretic peptides during experimental atrial tachycardia: role of developing tachycardiomyopathy. J Cardiovasc Electrophysiol (2004) 1.40

Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". Thromb Haemost (2009) 1.40

Evaluation of the electrocardiogram in identifying and quantifying lateral involvement in nonanterior wall infarction using cardiovascular magnetic resonance imaging. J Electrocardiol (2012) 1.39

MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res (2004) 1.39

Pulmonary vein isolation using transvenous catheter cryoablation for treatment of atrial fibrillation without risk of pulmonary vein stenosis. J Am Coll Cardiol (2003) 1.36

Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. Eur Heart J (2004) 1.36

Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol (2006) 1.31

Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J (2012) 1.30

Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol (2010) 1.28

Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol (2011) 1.27

Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med (2010) 1.24

Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace (2011) 1.22

The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med (2013) 1.20